Company profile
DexCom, Inc.
NASDAQ: DXCM · Healthcare · Medical - Devices
#65 of 1,422 Healthcare companies by revenue61st-percentile growth
EA Score
87AFH 87DQ 94GM 73SS 90
v0.1 · 65/100 weight · provisional
↑ Piotroski F, market scale · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$4.8B
Rev growth YoY (TTM)
+16.1%
Net income (FY)
$836.3M
Employees
11,100
as of 2026-08-05
Market cap
$32.8B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.7B$4.7B2025
Net income$836.3M$836.3M2025
Operating income$911.8M$911.8M2025
Total assets$6.3B$6.3B2025
Liabilities$3.6B$3.6B2025
Equity$2.7B$2.7B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is DexCom, Inc.’s revenue?
DexCom, Inc. booked $4.7B in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 17.9% net margin.
Peers · Healthcare
Bausch + Lomb Corporation67BThe Ensign Group, Inc.80B+Elanco Animal Health Incorporated66BIllumina, Inc.84B+IDEXX Laboratories, Inc.88AThe Cooper Companies, Inc.86ANeighbors
San Diego →Key facts
CEOJacob Steven Leach
SectorHealthcare
IndustryMedical - Devices
HeadquartersSan Diego, CA
ExchangeNASDAQ: DXCM
Employees11,100
IPO date2005-04-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.